My share of the year27 Nov 2018 07:16
Commenting on the news, Dr Dan Gooding, CEO of Nuformix, said: "The expanded licensing agreement demonstrates NSB's commitment to the commercialisation of NXP001 and its understanding of the commercial opportunity in China. This is a large, untapped and growing market, which in demographic terms has one third of global cancer patients. The milestone payment received validates Nuformix's business model and its commitment to reinvest initial revenues back into R&D, avoiding further fund-raising at this stage whilst maximising the potential value of its cocrystal platform."